NO20011555D0 - Orale doseringsformuleringer omfattende (2S,3S,5R)-2-(3,5- difluorfenyl)-3,5-dimetyl-2-morfolinol og en effektiv stabiliserende mengde alginsyre - Google Patents

Orale doseringsformuleringer omfattende (2S,3S,5R)-2-(3,5- difluorfenyl)-3,5-dimetyl-2-morfolinol og en effektiv stabiliserende mengde alginsyre

Info

Publication number
NO20011555D0
NO20011555D0 NO20011555A NO20011555A NO20011555D0 NO 20011555 D0 NO20011555 D0 NO 20011555D0 NO 20011555 A NO20011555 A NO 20011555A NO 20011555 A NO20011555 A NO 20011555A NO 20011555 D0 NO20011555 D0 NO 20011555D0
Authority
NO
Norway
Prior art keywords
morpholinol
difluorophenyl
dimethyl
alginic acid
oral dosage
Prior art date
Application number
NO20011555A
Other languages
English (en)
Other versions
NO20011555L (no
Inventor
Samuel Bruce Balik
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of NO20011555L publication Critical patent/NO20011555L/no
Publication of NO20011555D0 publication Critical patent/NO20011555D0/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Psychology (AREA)
  • Inorganic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Cosmetics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NO20011555A 1998-09-28 2001-03-27 Orale doseringsformuleringer omfattende (2S,3S,5R)-2-(3,5- difluorfenyl)-3,5-dimetyl-2-morfolinol og en effektiv stabiliserende mengde alginsyre NO20011555D0 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10211298P 1998-09-28 1998-09-28
PCT/EP1999/007117 WO2000018406A1 (en) 1998-09-28 1999-09-24 Oral dosage formulations comprising (2s,3s,5r) -2-(3,5- difluorophenyl) -3,5-dimethyl -2-morpholinol and an effective stabilizing amount of alginic acid

Publications (2)

Publication Number Publication Date
NO20011555L NO20011555L (no) 2001-03-27
NO20011555D0 true NO20011555D0 (no) 2001-03-27

Family

ID=22288187

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20011555A NO20011555D0 (no) 1998-09-28 2001-03-27 Orale doseringsformuleringer omfattende (2S,3S,5R)-2-(3,5- difluorfenyl)-3,5-dimetyl-2-morfolinol og en effektiv stabiliserende mengde alginsyre

Country Status (17)

Country Link
EP (1) EP1117407A1 (no)
JP (1) JP2002525328A (no)
KR (1) KR20010075385A (no)
CN (1) CN1328459A (no)
AR (1) AR022673A1 (no)
AU (1) AU6087399A (no)
BR (1) BR9914096A (no)
CA (1) CA2345638A1 (no)
CZ (1) CZ20011142A3 (no)
HU (1) HUP0103459A2 (no)
IL (1) IL142054A0 (no)
MA (1) MA26693A1 (no)
NO (1) NO20011555D0 (no)
PE (1) PE20001087A1 (no)
PL (1) PL346877A1 (no)
TR (1) TR200100863T2 (no)
WO (1) WO2000018406A1 (no)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1220673A2 (en) * 1999-10-13 2002-07-10 Glaxo Group Limited Morpholinol derivatives for the treatment of obesity
DE102008047910A1 (de) 2008-09-19 2010-03-25 Molkerei Meggle Wasserburg Gmbh & Co. Kg Tablettierhilfsstoff auf Laktose- und Cellulosebasis

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4597969A (en) * 1982-04-05 1986-07-01 Merck Sharp & Dohme Stabilization of unstable drugs or food supplements
GB8924528D0 (en) * 1989-10-31 1989-12-20 Wellcome Found Heterocyclic pharmaceutical compounds,preparation and use

Also Published As

Publication number Publication date
PL346877A1 (en) 2002-03-11
CA2345638A1 (en) 2000-04-06
TR200100863T2 (tr) 2001-07-23
AR022673A1 (es) 2002-09-04
BR9914096A (pt) 2001-07-31
CZ20011142A3 (cs) 2001-09-12
JP2002525328A (ja) 2002-08-13
WO2000018406A1 (en) 2000-04-06
HUP0103459A2 (hu) 2002-01-28
NO20011555L (no) 2001-03-27
PE20001087A1 (es) 2000-10-20
EP1117407A1 (en) 2001-07-25
AU6087399A (en) 2000-04-17
IL142054A0 (en) 2002-03-10
MA26693A1 (fr) 2004-12-20
KR20010075385A (ko) 2001-08-09
CN1328459A (zh) 2001-12-26

Similar Documents

Publication Publication Date Title
IL172695A0 (en) Novel medicament compositions, based on anticholinergically effective compounds and beta-mimetics
ID18666A (id) Penggunaan komposisi komposisi yang terdiri dari senyawa senyawa stabil yang efektif secara biologi
ID23299A (id) Formulasi-formulasi farmasi
DE69826683D1 (de) Therapeutische zusammensetzungen, enthaltend amlopidin und atorvastatin
DE69924999D1 (de) Lipasehemmer enthaltende pharmazeutische zusammensetzungen
IS6254A (is) Lyfjasamsetningar sem innihalda HMG afoxunarensímlata
IS5248A (is) Lyfjasamsetningar sem innihalda vorikónasól
FR2775596B1 (fr) Nouvelles compositions pharmaceutiques
NO20005913L (no) Legemiddelsammensetning
HK1034183A1 (en) Galenic formulations of meloxicam for oral administration.
ID27728A (id) Komposisi-komposisi mukoadesif oral yang mengandung bahan-bahan aktif gastrointestinal
ITMI982222A0 (it) Composizioni farmaceutiche orali contenenti buprenorfina
DE69822172D1 (de) Levosimendanhaltige oral anzuwendende arzneizusammensetzungen
DE69935609D1 (de) Formulierungen enthaltend cefuroxim-axetil
PT986537E (pt) Novos compostos heteroetinilenos e composicoes farmaceuticas e cosmeticas contendo-os
ATE254929T1 (de) Oralverabreichbare lösung von prucaloprid
NO20011555D0 (no) Orale doseringsformuleringer omfattende (2S,3S,5R)-2-(3,5- difluorfenyl)-3,5-dimetyl-2-morfolinol og en effektiv stabiliserende mengde alginsyre
AU1453600A (en) Solid oral dosage forms containing alginic acid and famotidine
ATE254453T1 (de) Oral anzuwendendes sertralinhaltiges konzentrat
NO20005164L (no) 2-metylpropionsyre-derivater og medisinske sammensetninger inneholdende det samme
DE69825193D1 (de) Pyridazinon-Verbindungen enthaltenden Zusammensetzungen zur oralen Verabreichung
HU9800623D0 (en) Oral application of "(+)-o-demethyl-tramadol as analgesic active component
KR970000226A (ko) S-이부프로펜의 경구용 제형
HUP0002459A3 (en) Salts of optically active sulfoxide derivative, pharmaceutical compositions containing them and use thereof
HUP0201265A3 (en) Salts of cis-[4-cyano-4-(3-cyclopentyloxy-4-metoxyphenyl) cyclohexan-1-carboxylate] and pharmaceutical compositions containing them

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application